Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Isofol Medical AB, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Isofol Medical Raises USD1.2 Million in Venture Financing 11
Licensing Agreements 12
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 12
Equity Offering 13
Isofol Medical Raises USD48.6 Million in IPO 13
Isofol Medical Raises USD4.7 Million in Public Offering of Shares 14
Isofol Medical AB – Key Competitors 15
Isofol Medical AB – Key Employees 16
Isofol Medical AB – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Financial Announcements 18
Nov 20, 2017: Isofol Medical: Interim Report January – September 2017 18
Aug 21, 2017: Isofol Medical: Interim Report 2017 (January 2017 – June 2017) 20
Mar 20, 2017: Isofol’s Year-End Report January – December 2016 22
Corporate Communications 24
Sep 11, 2018: New Chairman and extended board at Isofol Medical 24
Product News 25
11/27/2017: Isofol announces that an abstract regarding Modufolins efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018 25
10/03/2017: Isofol appoints Gustaf Albert as Chief Financial Officer 26
09/11/2017: Isofol announces that Modufolin as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities 27
08/24/2017: From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin in patients with metastatic colorectal cancer 28
08/18/2017: Isofols appoints Sven Erickson as Chief Commercial Officer 29
08/16/2017: Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin 30
07/03/2017: New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study 31
06/21/2017: Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin is evaluated in colorectal cancer 32
05/22/2017: Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting 33
05/03/2017: Isofol Accepted for Presentation of Abstract at the 2017 ASCO Annual Meeting 34
04/11/2017: Isofol has successfully completed the ISO-MTX-003 study in which Modufolin is evaluated as rescue therapy 35
02/08/2018: Isofol reports successful outcome from the scientific advice with the EMA 36
01/18/2018: Positive treatment results with Modufolin (arfolitixorin) will be published at a cancer congress in the US 37
01/11/2018: Isofol Announces Positive Efficacy Data For Modufolin (Arfolitixorin) In Patients Treated For Metastatic Colorectal Cancer 38
Product Approvals 39
Sep 04, 2017: Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin for treatment of metastatic colorectal cancer 39
Clinical Trials 40
Feb 19, 2018: Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin 40
Jan 17, 2018: Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin agreed 41
Jul 24, 2017: Isofol Announces that an Abstract about Modufolin in Osteosarcoma Treatment will be Presented at ESMO 2017 42
Jul 05, 2017: Isofol Has Enrolled And Dosed Its First Group Of Patients In The Ind-study Iso-ff-001 43
Jan 24, 2017: FDA Clears Isofol’S IND Application To Start Clinical Program Within Colorectal Cancer With Modufolin 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
Isofol Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Isofol Medical AB, Deals By Therapy Area, 2012 to YTD 2018 9
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Isofol Medical Raises USD1.2 Million in Venture Financing 11
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 12
Isofol Medical Raises USD48.6 Million in IPO 13
Isofol Medical Raises USD4.7 Million in Public Offering of Shares 14
Isofol Medical AB, Key Competitors 15
Isofol Medical AB, Key Employees 16
List of Figures
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9